Search results for "PULMONARY"

showing 10 items of 3030 documents

Role of Circulating miRNAs as Biomarkers in Idiopathic Pulmonary Arterial Hypertension: Possible Relevance of miR-23a

2015

Idiopathic pulmonary hypertension (IPAH) is a rare disease characterized by a progressive increase in pulmonary vascular resistance leading to heart failure. MicroRNAs (miRNAs) are small noncoding RNAs that control the expression of genes, including some involved in the progression of IPAH, as studied in animals and lung tissue. These molecules circulate freely in the blood and their expression is associated with the progression of different vascular pathologies. Here, we studied the expression profile of circulating miRNAs in 12 well-characterized IPAH patients using microarrays. We found significant changes in 61 miRNAs, of which the expression of miR23a was correlated with the patients’ …

AdultMaleAgingArticle SubjectNF-E2-Related Factor 2Idiopathic Pulmonary HypertensionBiologyBiochemistryPulmonary function testingmicroRNAmedicineGene silencingHumansFamilial Primary Pulmonary Hypertensionlcsh:QH573-671Cells CulturedAgedlcsh:CytologySuperoxide DismutaseGene Expression ProfilingCytochromes cCell BiologyGeneral MedicineMiddle Agedmedicine.diseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaGene expression profilingMicroRNAsmedicine.anatomical_structureHeart failureImmunologyVascular resistanceBiomarker (medicine)FemaleBiomarkersHeme Oxygenase-1Research ArticleTranscription FactorsOxidative Medicine and Cellular Longevity
researchProduct

PGC-1α Induction in Pulmonary Arterial Hypertension

2012

Idiopathic Pulmonary arterial hypertension (IPAH) is characterized by the obstructive remodelling of pulmonary arteries, and a progressive elevation in pulmonary arterial pressure (PAP) with subsequent right-sided heart failure and dead. Hypoxia induces the expression of peroxisome proliferator activated receptorγcoactivator-1α(PGC-1α) which regulates oxidative metabolism and mitochondrial biogenesis. We have analysed the expression of PGC-1α, cytochrome C (CYTC), superoxide dismutase (SOD), the total antioxidant status (TAS) and the activity of glutathione peroxidase (GPX) in blood samples of IPAH patients. Expression of PGC-1αwas detected in IPAH patients but not in healthy volunteers. Th…

AdultMaleAgingmedicine.medical_specialtyArticle SubjectHypertension PulmonaryPeroxisome proliferator-activated receptorBiologyBiochemistrySuperoxide dismutaseChloridesInternal medicinemedicineHumansFamilial Primary Pulmonary Hypertensionlcsh:QH573-671Heat-Shock ProteinsAgedchemistry.chemical_classificationGlutathione Peroxidaselcsh:CytologySuperoxide DismutaseGlutathione peroxidaseAge FactorsCytochromes cCell BiologyGeneral MedicineHypoxia (medical)Middle Agedmedicine.diseasePulmonary hypertensionPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaEndocrinologymedicine.anatomical_structurechemistryMitochondrial biogenesisHeart failurebiology.proteinVascular resistanceFemaleVascular Resistancemedicine.symptomTranscription FactorsResearch ArticleOxidative Medicine and Cellular Longevity
researchProduct

RUPTURE OF A LEFT SINUS OF VALSALVA ANEURYSM INTO THE PULMONARY ARTERY.

2006

Sinus of Valsalva aneurysm is a rare congenital defect and the diagnosis is usually made after it ruptures. Very few cases of non-complicated sinus of Valsalva aneurysm have been published. The anomaly most often involves the right coronary sinus and less frequently the non-coronary sinus. A case with left sinus of Valsalva has not been reported. Since the aortic valve occupies a central position in the base of the heart, rupture of a sinus of Valsalva aneurysm can occur in any of the four heart chambers. Rupture into the pulmonary artery is very rare and is mostly associated with other congenital cardiopathies. ª 2005 The European Society of Cardiology. Published by Elsevier Ltd. All right…

AdultMaleAortic valvemedicine.medical_specialtyHeart.chambersAneurysm RupturedPulmonary ArteryMyocardial ruptureDiagnosis DifferentialAneurysmInternal medicinemedicine.arteryHIV Seropositivityotorhinolaryngologic diseasesHumansMedicineRadiology Nuclear Medicine and imagingcardiovascular diseasesHeart AneurysmSinus (anatomy)Coronary sinusbusiness.industryGeneral MedicineSinus of Valsalvamedicine.diseaseAneurysmEchocardiography Doppler Colorbody regionsmedicine.anatomical_structurePulmonary arterycardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyRupture into the pulmonary artery
researchProduct

Lorcainide. I. Saturable presystemic elimination.

1979

AdultMaleBenzeneacetamidesAdministration OralPharmacologyHepatic VeinsIn Vitro TechniquesPulmonary ArteryLorcainidePiperidinesMedicineHumansPharmacology (medical)Aorta AbdominalAortaAgedPharmacologybusiness.industryArrhythmias CardiacBlood ProteinsMiddle AgedBloodInjections IntravenousAcetanilidesFemalebusinessAnti-Arrhythmia Agentsmedicine.drugProtein BindingClinical pharmacology and therapeutics
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma

2003

BACKGROUND. The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lymphoma has been associated with conflicting toxicity reports. METHODS. One hundred forty-three patients were evaluated clinically and had favorable Stage IA or IIA Hodgkin lymphoma. Ninety-three patients were treated with the standard VBM schedule combined with extended-field radiotherapy (EFRT), leaving the choice of the therapeutic sequence free. Fifty subsequent patients were treated with a slightly modified VBM schedule (VbMp) combined with RT limited to involved fields (IF-RT) and delivered only after the end of chemotherapy. In the VbMp sched…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPulmonary toxicitymedicine.drug_classmedicine.medical_treatmentchemotherapyBleomycinGastroenterologyAntimetaboliteBleomycinchemistry.chemical_compoundHodgkinPrednisoneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLungradiotherapyAgedChemotherapybusiness.industryHodgkin; chemotherapy; radiotherapy; toxicitytoxicityMiddle AgedCombined Modality TherapyHodgkin DiseaseSurgeryVinblastineRegimenMethotrexateTreatment OutcomeOncologychemistryVincristineFemaleMethotrexateNeoplasm Recurrence Localbusinessmedicine.drugCancer
researchProduct

Sarcoma of the pulmonary artery: Report of two cases and a review of the literature

1992

Primary tumours of the pulmonary arteries are rare neoplasms seldom diagnosed during the patient's life time. We report on two cases of pulmonary artery sarcomas diagnosed during life time of the respective patients in intra-operative frozen sections by histopathological examination. Case 1 was of a 55-year-old man with a fibrosarcoma originating from the main pulmonary trunk. Case 2 was of a 43-year-old woman with a malignant fibrous histiocytoma originating from the right pulmonary artery. In both patients a radical tumour resection under cardiopulmonary bypass was attempted. Both patients, however, had a local tumour recurrence and died 18 months (patient 1) and 6 months (patient 2) afte…

AdultMaleCancer Researchmedicine.medical_specialtyTumor resectionPulmonary Arterylaw.inventionlawInternal medicinemedicine.arterymedicineCardiopulmonary bypassHumansVascular DiseasesFibrosarcomaFrozen section procedureHematologybusiness.industrySarcomaGeneral MedicineMiddle Agedmedicine.diseaseRight pulmonary arterySurgeryOncologyPulmonary arteryFemaleRadiologySarcomabusinessJournal of Cancer Research and Clinical Oncology
researchProduct

Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study

2016

In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. The intention was to find as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyYoung Adult03 medical and health sciences0302 clinical medicineVenous thrombosisLow Molecular Weight HeparinHumansMedicineacute leukemiacardiovascular diseaseseducationAgedAged 80 and overVenous ThrombosisAcute leukemiaeducation.field_of_studyAcute leukemiaChemotherapyLeukemiabusiness.industrylow molecular weight heparinIncidenceIncidence (epidemiology)Disease ManagementVenous ThromboembolismHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryVenous thrombosisOncology030220 oncology & carcinogenesisAcute DiseaseFemaleacute leukemia; low molecular weight heparin; Venous thrombosisbusinessSettore MED/15 - Malattie del SangueVenous thromboembolismLeukemia &amp; Lymphoma
researchProduct

Clinical application of a new rheolytic thrombectomy catheter system for massive pulmonary embolism

1999

AdultMaleCardiac Catheterizationmedicine.medical_specialtyPulmonary ArterymedicineHumansRadiology Nuclear Medicine and imagingIntensive care medicineAgedThrombectomybusiness.industryCoronary ThrombosisHemodynamicsGeneral MedicineMiddle Agedmedicine.diseasePulmonary embolismRadiographyCatheterEmbolismEvaluation Studies as TopicFemaleRadiologyPulmonary EmbolismRheologyCardiology and Cardiovascular MedicinebusinessCatheterization and Cardiovascular Interventions
researchProduct

In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages

2010

Abstract Background In the recessive aminoaciduria Lysinuric Protein Intolerance (LPI), mutations of SLC7A7/y+LAT1 impair system y+L transport activity for cationic amino acids. A severe complication of LPI is a form of Pulmonary Alveolar Proteinosis (PAP), in which alveolar spaces are filled with lipoproteinaceous material because of the impaired surfactant clearance by resident macrophages. The pathogenesis of LPI-associated PAP remains still obscure. The present study investigates for the first time the expression and function of y+LAT1 in monocytes and macrophages isolated from a patient affected by LPI-associated PAP. A comparison with mesenchymal cells from the same subject has been a…

AdultMaleCellular differentiationlcsh:MedicinePulmonary Alveolar ProteinosisBiologyMonocytesPathogenesisYoung AdultMacrophages AlveolarmedicineHumansGenetics(clinical)Pharmacology (medical)Amino Acid Metabolism Inborn ErrorsCells CulturedGenetics (clinical)Medicine(all)chemistry.chemical_classificationResearchFusion Regulatory Protein 1 Light ChainsLysinelcsh:RMesenchymal stem cellAmino Acid Transport System y+LGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationGeneral Medicinemedicine.diseaseLysinuric protein intoleranceMolecular biologyAmino acidGranulocyte macrophage colony-stimulating factorchemistryAminoaciduriaImmunologyPulmonary alveolar proteinosismedicine.drugOrphanet Journal of Rare Diseases
researchProduct